An expanded role for neuroimaging in the evaluation of memory impairment

American Journal of Neuroradiology

Volumn 34, Issue 11, 2013, Pages 2075-2082

  Desikan, Rahul S ^a   Rafii, M S ^b   Brewer, J B ^a,b   Hess, C P ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; BIOLOGICAL MARKER; SOLANEZUMAB;

ALZHEIMER DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; DRUG CLEARANCE; FRONTOTEMPORAL DEMENTIA; HUMAN; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; REVIEW;

ALZHEIMER DISEASE; BRAIN; EVIDENCE-BASED MEDICINE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MEMORY DISORDERS; MOLECULAR IMAGING; NEUROIMAGING;

EID: 84888176679     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3644     Document Type: Review

References (63)

1. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009;66:1447-55
2. Petersen RC. Clinical practice. Mild cognitive impairment. N Eng J Med 2011;364:2227-34
3. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr 1907;64:146-48
4. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011;6:3:77sr1
5. Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 2009;106:4012-17
6. Kuchibhotla KV, Goldman ST, Lattarulo CR, et al. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008;59:214-25 (Pubitemid 352033686)
7. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;64:632-44
8. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488:96-99
9. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988;38:1682-87 (Pubitemid 18265029)
10. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-39
11. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23 (Pubitemid 351978111)
12. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
13. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316:750-54 (Pubitemid 46717684)
14. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010;142:387-97
15. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol 2011;70:657-61
16. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-β-associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol 2012;69:709-13
17. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062-64
18. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001;17:101-18 (Pubitemid 33063515)
19. Sperling RA, Aisen PS, Beckett LA. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92
20. Knopman DS, DeKosky ST, Cummings JL. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53 (Pubitemid 32405708)
21. Vemuri P, Jack CR Jr. Role of structural MRI in Alzheimer's disease. Alzheimers Res Ther 2010;2:23
22. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008;71:743-49
23. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341-55 (Pubitemid 34162530)
24. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11-22 (Pubitemid 38018050)
25. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968-80 (Pubitemid 44183792)
26. McEvoy LK, Brewer JB. Quantitative structural MRI for early detection of Alzheimer's disease. Expert Rev Neurother 2010;10:1675-88
27. Holland D, McEvoy LK, Dale AM, et al. Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp 2011;33:2586-602
28. Brewer JB, Magda S, Airriess C, et al. Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. AJNR Am J Neuroradiol 2009;30:578-80
29. Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10:785-96
30. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 2003;100:12462-67 (Pubitemid 37271582)
31. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′-methyl- aminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-92 (Pubitemid 36368896)
32. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-44
33. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-45 (Pubitemid 351806448)
34. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009;21:117-28
35. Johnson KA, Fox NC, Sperling RA, et al. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006213
36. Holtzman DM. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging 2011;32 Suppl 1:S4-9
37. Laino C. News from the American Neurological Association Annual Meeting: anti-amyloid-beta drug modestly slows cognitive decline in mild to moderate AD. Neurol Today 2012;12:34-38
38. Jack CR Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement 2011;7:474-85.e4
39. Jack CR Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012;263:344-61
40. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27
41. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-69
42. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-79
43. Highlights of prescribing information: Amyvid (florbetapir F18 injection). Silver Spring, MD: Food and Drug Administration (http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/202008s000lbl.pdf)
44. Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012;2:a006338
45. Storandt M, Mintun MA, Head D, et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66:1476-81
46. Schott JM, Bartlett JW, Fox NC, et al. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ 1-42. Ann Neurol 2010;68:825-34
47. Tarawneh R, D'Angelo G, Macy E, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 2011;70:274-85
48. McEvoy LK, Brewer JB. Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging Med 2012;4:343-57
49. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804
50. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011;17:1060-65
51. Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009;72:1048-55
52. Costafreda SG, Dinov ID, Tu Z, et al. Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage 2011;56:212-19
53. den Heijer T, van der Lijn F, Koudstaal PJ, et al. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010;133:1163-72
54. Desikan RS, Cabral HJ, Fischl B, et al. Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease. AJNR Am J Neuroradiol 2009;30:532-38
55. Heister D, Brewer JB, Magda S, et al. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011;77:1619-28
56. Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-toprogression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-48
57. Kovacevic S, Rafii MS, Brewer JB, et al. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord 2009;23:139-45
58. Sluimer JD, van der Flier WM, Karas GB, et al. Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. Eur Radiol 2009;19:2826-33
59. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009;73:294-301
60. Westman E, Cavallin L, Muehlboeck JS, et al. Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS One 2011;6:e22506
61. Dickerson BC, Stoub TR, Shah RC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011;76:1395-402
62. Dickerson BC, Wolk DA. Alzheimer's Disease Neuroimaging Initiative. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012;78:84-90
63. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-711 (Pubitemid 46691097)